一种新型冠状病毒类病毒结构疫苗的成药可能性

Drugability of a virus-like structure based SARS-CoV-2 vaccine

目的探讨新型冠状病毒类病毒结构疫苗中的mRNA和蛋白使用剂量对小鼠免疫效果的影响, 以期确定最佳的mRNA和蛋白使用剂量及成药可能性。方法用ADT-脂质纳米颗粒递送系统装载和包封不同剂量的蛋白和mRNA, 转染不同细胞系检测相应抗原表达情况, 以及免疫动物检测血清的特异性抗体效价。结果类病毒结构疫苗在包裹较小剂量mRNA(10~20 μg/剂)并装载蛋白(5 μg/剂)的情况下, 能够特异性地激活小鼠树突状细胞, 同时激活天然免疫及获得性免疫保护。结论此研究的类病毒结构疫苗在小鼠实验中具有良好的免疫原性和抗体诱导功能, 具有成为新型疫苗的可能性。

ObjectiveTo investigate the best immune effectiveness of the virus-like structure(VLS)mRNA vaccine against severe acute respiratory syndrome coronavirus 2 in mice,using vaccine containing different dosages of mRNA and protein,to determine the drugability of this vaccine.MethodsADT-lipid nanoparticle delivery system was applied to encapsulate different doses of mRNA and protein.It was used to transfect different cell lines for detecting the expression of antigens coded by mRNA and immunize BALB/c mice to evaluate antibody response elicited by VLS vaccine.ResultDendritic cell activation was found in BALB/c mice immunized by VLS vaccine encapsulated 10-20μg mRNA and 5μg protein in vivo,while the activation of innate and adaptive immunity was observed in mice.ConclusionThe VLS mRNA vaccine can become a novel candidate vaccine,with potent immunogenicity and antibody stimulating ability in mice.